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Abstract
Background: Multiple sclerosis (MS) is the most common inflammatory disease of the central nervous system in
young adults that may lead to progressive disability. Since pharmacological treatments may have substantial side
effects, there is a need for complementary treatment options such as specific dietary approaches. Ketone bodies
that are produced during fasting diets (FDs) and ketogenic diets (KDs) are an alternative and presumably more
efficient energy source for the brain. Studies on mice with experimental autoimmune encephalomyelitis showed
beneficial effects of KDs and FDs on disease progression, disability, cognition and inflammatory markers. However,
clinical evidence on these diets is scarce. In the clinical study protocol presented here, we investigate whether a KD
and a FD are superior to a standard diet (SD) in terms of therapeutic effects and disease progression.
Methods: This study is a single-center, randomized, controlled, parallel-group study. One hundred and eleven
patients with relapsing–remitting MS with current disease activity and stable immunomodulatory therapy or no
disease-modifying therapy will be randomized to one of three 18-month dietary interventions: a KD with a
restricted carbohydrate intake of 20–40 g/day; a FD with a 7-day fast every 6 months and 14-h daily intermittent
fasting in between; and a fat-modified SD as recommended by the German Nutrition Society. The primary outcome
measure is the number of new T2-weighted MRI lesions after 18 months. Secondary endpoints are safety, changes
in relapse rate, disability progression, fatigue, depression, cognition, quality of life, changes of gut microbiome as
well as markers of inflammation, oxidative stress and autophagy. Safety and feasibility will also be assessed.
Discussion: Preclinical data suggest that a KD and a FD may modulate immunity, reduce disease severity and
promote remyelination in the mouse model of MS. However, clinical evidence is lacking. This study is the first
clinical study investigating the effects of a KD and a FD on disease progression of MS.
Trial registration: ClinicalTrials.gov, NCT03508414. Retrospectively registered on 25 April 2018.
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Introduction
Multiple sclerosis (MS) is the most common chronic in-
flammatory autoimmune disease of the central nervous
system. It leads to neurodegeneration and is a major
cause of progressive disability and early retirement in
young adults [1–3]. According to estimates, more than 2
million people worldwide are affected [4]. Relapsing–re-
mitting MS (RRMS) is the most common form of MS
and is characterized by relapses and periods of remission
as well as systemic inflammation of the central nervous
system and progressive neurodegeneration from the
earliest disease stages [5, 6].
Currently, there is no cure for MS, but several immu-
nomodulatory therapies are available that may slow dis-
ease progression [7]. However, all of them may have
substantial side effects and patients respond differently
due to the complex nature of the disease. Consequently,
there is a need for complementary therapies such as spe-
cific diets that may reduce MS symptoms, improve the
patient’s quality of life and even delay disease progres-
sion. A recent review reported that up to 70% of MS pa-
tients already use alternative and complementary
medicine [8].
It is widely accepted that a combination of genetic
susceptibility and environmental factors causes MS
[9]. That nutrition might be among these factors is
supported by the fact that MS is more frequent in
western countries than in less-developed nations
[10]. The so-called western diet is high in energy,
saturated fats and sugars. Of note, a meal high in
fat and refined carbohydrates has been shown to
cause a more pronounced postprandial insulin se-
cretion and enhanced inflammation compared to a
meal high in fiber and fruits in healthy lean subjects
[11]. In line with this, a 12-week ketogenic diet
(KD) decreased insulin resistance and several serum
inflammatory markers in overweight men and
women [12].
These are important findings since insulin resistance
seems to be more common in MS patients than in
healthy controls and is associated with higher Expanded
Disability Status Scale (EDSS) scores [13, 14]. Further-
more, elevated serum levels of the pro-inflammatory
cytokine IL-17 in MS patients [14] may contribute to the
impaired glucose and insulin metabolism in MS [15].
The cerebral glucose hypometabolism that occurs in
MS patients [16–18] is thought to reflect mitochondrial
dysfunction in neuronal cells [19]. Although the mech-
anism is not yet defined, it is feasible that neurodegener-
ative processes driven partly by oxidative stress
contribute to this mitochondrial dysfunction [20]. In-
deed, several studies have demonstrated increased
markers of oxidative stress and decreased compensatory
antioxidative capacity in MS patients [14, 21–23].
Profound reduction of either overall calorie or carbo-
hydrate intake decreases glucose and insulin levels,
thereby driving the body to produce ketone bodies from
internal or external fats. These ketone bodies provide an
alternative energy source for the brain. They might even
be more efficient (per unit oxygen) than glucose [24].
Furthermore, ketone bodies seem to stimulate mito-
chondrial biogenesis and reduce mitochondrial perme-
ability [25, 26].
KDs and fasting diets (FDs) both drastically reduce
carbohydrate intake and it has been suggested that the
resulting ketone bodies facilitate the regeneration of
demyelinated axons [20]. It is thus feasible that either of
these dietary approaches could have a therapeutic bene-
fit in MS patients.
Fasting not only induces ketosis, but might also acti-
vate autophagy in the brain, liver and muscle [27].
Macroautophagy is a key quality-control pathway in cells
through which nonnuclear parts of the cell and cytoplas-
mic macromolecules are renewed and mobilized, re-
spectively. It is thought to mediate the anti-aging effects
of calorie restriction [28].
Since some of the effects of fasting can be replicated
with a KD, autophagy might also be relevant for KDs.
Indeed, current evidence from a rat model suggests that
a KD can attenuate seizure-induced neuronal injury via
autophagy [29].
The KD was originally conceptualized to mimic the
biochemical effects associated with fasting [30] and was
used as an alternative treatment in pharmaco-resistant
childhood epilepsy as early as the 1920s [31]. Since then,
KDs have also been shown to improve symptoms in
other neurodegenerative diseases such as Alzheimer’s
disease and Parkinson’s disease [32, 33].
In the case of MS, there is preclinical evidence for the
efficacy of KDs and FDs from experimental autoimmune
encephalomyelitis (EAE), the established animal model
of MS. A KD slowed disease progression, improved
motor disability and hippocampal atrophy, reversed le-
sions and suppressed inflammatory cytokines and react-
ive oxygen species [34]. A fasting mimicking diet was
shown to delay onset and slow disease progression. This
was accompanied by increased corticosterone levels,
autoreactive lymphocyte apoptosis and oligodendrocyte
regeneration during the fasting [35]. These findings are
supported by other EAE studies showing beneficial ef-
fects of intermittent fasting and chronic calorie restric-
tion [36–38].
Changes in the gut microbiome are associated with many
disease states, including autoimmune diseases such as MS,
and the gut microbiome is intricately linked to our immune
system and inflammatory responses. The typical western
diet is associated with gut microbial imbalance (dysbiosis),
low-grade inflammation and neuroinflammation [39].
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Interestingly, recent studies have shown that gut dysbiosis
can also occur in MS patients [40–42]. Both KDs and FDs
may positively affect the gut microbiota by enhancing gut
microbial diversity [42, 43]. Thus, changes of the gut micro-
biome could be implicated in the effects of our dietary
regimens.
We have already obtained clinical evidence for the
feasibility and safety of KDs and FDs in MS patients and
showed that they might improve health-related quality
of life [35]. Another more recent pilot study which
tested the safety and tolerability of a modified Atkins
diet found decreased body mass index, body fat mass, fa-
tigue and depression scores in 20 RRMS patients. This
was, however, an uncontrolled study with just a 6-
month intervention period, which cannot corroborate ef-
fects on disease progression [44].
Here, we present the protocol of a randomized, con-
trolled clinical study investigating the effects of a KD
and a FD compared to a standard diet (SD) in RRMS.
The SD is a healthy, predominantly vegetarian diet that
follows the recommendations of the German Nutrition
Society (DGE). MS patients adhering to a similar diet for
12 months showed improved body mass index, metabolic
markers and fatigue but no changes in brain MRI out-
comes [45].
Thus, we hypothesize that KDs and FDs are superior
to the SD with respect to new lesions on cranial T2-
weighted MRI after 18 months compared to baseline.
We further hypothesize differential effects of our inter-
ventions in men and women, because of sex-specific
metabolic differences (e.g. fat and carbohydrate metabol-
ism). We further expect larger treatment effects in pa-
tients without MS medication.
Secondary endpoints are safety aspects of the dietary
interventions, brain volume, annualized relapse rate, dis-
ability progression, changes in gut microbiome, metabo-
lomics of stool and blood, immunological effects,
cognition, fatigue, depression, muscle strength, walking
endurance and quality of life.
Methods
Study design
This is a single-center, randomized, controlled, three-
armed, parallel-group study conducted at the NeuroCure
Clinical Research Center at Charité—Universitätsmedi-
zin Berlin. Recruitment started in April 2017 (Clinical-
Trials.gov identifier: NCT03508414). Patients are
recruited from all over Germany. Recruitment strategies
include specific study calls on the website of the German
Multiple Sclerosis Society and the distribution of study
flyers in specialized neurological practices as well as in-
formation events and lectures for patients. We intend to
randomize 111 RRMS patients to one of three 18-month
dietary interventions: a KD with a carbohydrate intake
restricted to 20–40 g/day; a FD with a 7-day fast every 6
months and 14-h daily intermittent fasting in between;
and a SD that is predominantly vegetarian and fat-
modified as recommended by the German Nutrition So-
ciety. The institutional review board of Charité—Univer-
sitätsmedizin Berlin approved the study and written
informed consent is obtained from all participants prior
to study entry (Additional files 1 and 2). The study is
conducted in accordance with the Declaration of
Helsinki in its currently applicable version, the guide-
lines of the International Conference on Harmonization
of Good Clinical Practice (ICH-GCP) and applicable
German laws. For further details refer to the SPIRIT
checklist (Additional file 3).
Participants
Patient information and informed consent have been
prepared in accordance with the guidelines of the in-
stitutional review board of Charité—Universitätsmedi-
zin Berlin. Potential participants receive both forms at
least 24 h before a consultation with a study physician
who personally explains all study procedures. If he or
she is willing to participate and had sufficient time to
ask questions, written informed consent is given.
Afterward, inclusion and exclusion criteria are
assessed. The main inclusion criteria are a definite
diagnosis of RRMS according to the 2017 McDonald
criteria [46], a stable immunomodulatory therapy or
no disease-modifying therapy for at least 6 months, an
EDSS score below 4.5 [47] and disease activity within
the last 2 years before study entry. This is defined as
at least one new lesion on brain MRI and/or at least
one relapse. Participants are recruited in cohorts of
15–25 patients.
Complete list of inclusion criteria
 Relapsing–remitting MS
 18–65 years of age
 EDSS < 4.5
 Stable immunomodulatory therapy or no disease-
modifying therapy ≥ 6 months before study entry
 ≥ 1 relapse or ≥ 1 new T2 lesion or ≥ 1 contrast-
enhancing lesion on MRI within the last 2 years
 Agreement that possible incidental findings will be
communicated
 Body mass index between 19 and 45 kg/m2
 Ability to give verbal and written consent
 Health insurance
Complete list of exclusion criteria
 Start or change of immunomodulatory therapy < 6
months before or during the study
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 Relapse or cortisone treatment within 30 days before
study entry
 Clinically relevant metabolic, progressive or
malignant diseases
 Intake of > 1 g/day omega-3 fatty acid supplements
 Significant cognitive-cooperative impairment
 Insulin-dependent diabetes mellitus (type I)
 Participation in another interventional study
 Weight loss diet or loss of more than 5 kg within 2
months before study entry
 Insufficient mental ability for cooperation
 Eating disorders
 Kidney stones
 Therapy with oral anticoagulants
 Pregnancy and breastfeeding
 Suspected lack of compliance
 Smokers (> 5 cigarettes per day)
 Known alcohol and drug abuse
 Inability to give informed consent or apply to the
study protocol
 Contraindications for MRI such as metallic
implants, cardiac pacemakers and claustrophobia
Retention of patients is promoted by close and fre-
quent contact with their nutritional counselor and study
physician via telephone, email and study visits. In case of
relevant issues, visits outside the study schedule are
offered.
Discontinuation criteria are withdrawal of consent,
subsequent occurrence of an exclusion criterion (e.g.
change of immunomodulatory therapy), lack of compli-
ance and medical reasons for stopping the intervention.
For all three groups, compliance is defined as attend-
ing at least 8 of 10 group sessions and each of six study
visits. Food records measure compliance to the pre-
scribed intervention. In the KD group, the majority of
blood ketone measurements should be ≥ 0.5 mmol/L.
For the FD group, there are regular additional meetings
during each of the three fasting periods. These meetings
have to be attended, enabling the physician and the
counselor to evaluate compliance.
We offer patients who meet a discontinuation criterion
to attend the remaining study visits for follow-up outside
the study protocol. We assess all outcomes except for
exploratory blood parameters (autophagy, oxidative
stress) in these patients.
Randomization
Eligibility of patients will be determined at the screening
visit by a trained physician. Afterward, randomization is
done in three strata to distribute possible confounding
factors equally to the dietary interventions. Strata are sex
(man or woman), MS medication (yes or no) and lesion
load (< 15 or ≥ 15 lesions) in the baseline brain MRI
scan. We use a stratified block randomization with
variable block length. This will ensure a homogeneous
distribution of interventions over these strata. An exter-
nal statistician who is not involved in the study carries
out the randomization according to predefined
randomization lists.
Dietary interventions
Nutritional counseling for all three interventions takes
place in small groups within 10 sessions over 18 months
(five sessions in months 1–3, five sessions in months 4–
18). The group setting facilitates exchange between pa-
tients, management of dietary challenges, monitoring of
compliance and recording of adverse events. Between
the group sessions, patients have the possibility to con-
tact their nutritional counselor via email or telephone at
any time.
 KD. During nutritional counseling, patients are
instructed to start by limiting carbohydrate intake to
just 20 g/day for 4 weeks in order to establish
ketosis. Then, patients increase their carbohydrate
intake by 5 g each week until they reach their
individual maximum (approximately 40 g) to
maintain stable ketosis. All carbohydrates relevant
for elevating blood glucose are limited to 40–50 g/
day. In addition, the glycemic index and glycemic
load of carbohydrates have to be below 50 and 6,
respectively. This ketogenic diet is equivalent to a
traditional ketogenic diet, but with a liberalized
macronutrient composition of 70–80% fats, 15–20%
proteins and 5–10% carbohydrates (compared to a
traditional ketogenic diet with 90% fat, 6% proteins
and 4% carbohydrates). To aid in the adjustment
and determine their individual carbohydrate intake
limits, patients receive a hand-held ketone-meter to
measure and record blood concentrations of ketone
body β-hydroxybutyrate at regular intervals. Values
should be between 0.5 and 3.0 mmol/L.
 FD. Patients in the FD group fast for 7 days every 6
months. During this intensive fasting episode,
patients only consume vegetable juices and vegetable
broth, yielding a daily calorie intake between 200
and 350 kcal. Tea and water is available ad libitum
to ensure sufficient fluid intake. Two days before
and 3 days after fasting, patients eat a low-calorie
vegetarian diet for preparation and aftercare. The
fasting is initialized by an intestinal clearing with lax-
atives (e.g. Glauber’s Salt by FX-Passage). Outside
these intensive fasting episodes, patients intermit-
tently fast for 14 h daily on 7 days of the week in
order to maintain fasting effects. For compliance
reasons, participants may take one “cheat day” per
week at which they follow the fasting rules less
Bahr et al. Trials            (2020) 21:3 Page 4 of 9
strictly. During intermittent fasting, patients are
counseled to eat a diet according to the recommen-
dations of the DGE (equivalent to the SD group).
Patients additionally attend group sessions every
other day during fasting. A physician and a dietician
with expertise on fasting monitor these sessions.
During the first intensive fasting episode, these ses-
sions are every other day. In the subsequent fasting
episodes, the meetings are less frequent (three or
four meetings).
 SD. Patients are counseled to adhere to a healthy,
non-calorie-restricted diet according to the rec-
ommendations of the DGE. This diet is predom-
inantly vegetarian with reduced consumption of
meat, animal fats, eggs and egg products. Low-fat
milk and dairy products are recommended to pro-
vide calcium. Dietary recommendations are de-
signed to modify the omega-6 to omega-3 fatty
acid ratio to 5:1.
Adverse events
There are no major risks for patients participating in this
study. Minor adverse events of a ketogenic diet and fast-
ing can be headaches, feelings of hunger, fatigue, irrit-
ability and dizziness. These side effects are transient and
will stop after a few days. Patients will be asked for toler-
ability of the interventions and any adverse events will
be recorded. We do not expect serious adverse events
due to our dietary interventions.
Outcome parameters
Our primary endpoint is the number of new lesions on
cranial T2-weighted MRI after 18 months compared to
baseline. The secondary MRI endpoint is brain atrophy
determined by percentage brain volume change. All MRI
scans will be performed in a 3-Tesla MRI scanner (Tim
Trio; Siemens, Erlangen, Germany) and will be assessed
by an experienced evaluator who is blinded to both clin-
ical data and interventional allocation.
Additional secondary endpoints are the annualized re-
lapse rate, neurological–functional disability progression
(EDSS, Multiple Sclerosis Functional Composite), cogni-
tion (Symbol Digit Modalities Test), fatigue (Fatigue
Severity Scale), depression (Beck Depression Inventory
II), muscle strength (handgrip dynamometer), walking
endurance (6-min walk test) and quality of life (MSQoL-
54). In a subset of patients, we will evaluate glucose vari-
ability from continuous glucose measurements over 14
days (FreeStyle Libre Sensors; Abbott). All endpoints will
be assessed at baseline, 9 and 18months by trained and
experienced personnel.
For safety monitoring, body weight and composition,
dietary intake and vital signs are recorded at regular in-
tervals as well as routine laboratory tests of blood count,
kidney and liver parameters in peripheral venous blood.
In addition, we want to investigate metabolic, hormonal
and immunological effects of the diets. For this, periph-
eral blood mononuclear cells are isolated for further
analysis. In addition, markers of oxidative stress, espe-
cially reaction products of anti-oxidative enzymes, are of
interest. The polyamine level and cell metabolites will be
measured as secondary markers of nutrient availability
and autophagy activation in the cell. Stool samples are
collected for 16s rRNA sequencing. For a detailed over-
view of assessments and endpoints, see Table 1.
We will inform participants about any conspicuous
findings and refer them to their general practitioner for
further treatment. After completion of the study, partici-
pants have the possibility to be referred to appropriate
outpatient nutritional counseling.
Power calculation
Based on the results of other MS studies in our research
center in comparable patient cohorts, an average of
three new T2 lesions after 18 months is expected in the
SD group. Sample size was calculated with the Wilcoxon
(Mann–Whitney) rank-sum test and the significance
level was adjusted (Bonferroni) for the two comparisons
(KD vs. SD and FD vs. SD). With a sample size of 33 pa-
tients per group and a two-sided significance level of
0.025, there is a power of 80% to detect a probability of
0.72 that an observation from group 1 is smaller than
that from group 2. This corresponds to a standardized
effect size of 0.83 and an expected mean difference in
the number of new T2 lesions in each of the interven-
tion groups of 0.5 compared to the SD group after 18
months (Query Advisor 7.0). We expect a dropout rate
of approximately 10% and therefore plan to enroll 37 pa-
tients per group, 111 patients in total.
Data management
Each participant will receive a unique identifier upon
study entry. This identifier will be used for all data docu-
mentation to ensure the participant’s confidentiality.
Data will be gathered in source documents and then
transferred onto paper case report forms. Later, all data
will be digitized and stored in a central database. To im-
prove accuracy of data entry, entries will be verified for
proper format and expected range as well as double-
checked. Overall data quality will be assured by inde-
pendent monitoring throughout the study. However, due
to the minimal risks of our dietary interventions, a data
monitoring committee is deemed unnecessary. Data will
be stored for 10 years after study completion and then
deleted. Any modification to the current study protocol
will be submitted to the institutional review board, all
trial participants and the trial investigators.
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We only obtain consent for usage of data and samples
for the research question described in this protocol.
Thus, we do not intend to use participant data or bio-
logical samples in ancillary studies.
Results will be personally explained to all study partici-
pants, presented on national and international conferences,
published in peer-reviewed journals, and disseminated to
neurologists and the medical laity. We will comply with the
official eligibility guidelines for authorship for all publica-
tions and do not intend to use professional writers.
Data analysis
Confirmatory analysis will be conducted based on the
intention-to-treat (ITT) population. The aim is to show
that KDs and FDs are superior to the SD, meaning that
the number of new T2 lesions after 18 months of dietary
intervention adjusted for the baseline value is lower in
the KD and FD groups than in the SD group. Although
the sample size calculation was conservatively based on
the Mann–Whitney U test, the final analysis of the pri-
mary endpoint will be based on non-parametric analysis
of covariance (ANCOVA) on ranks with the treatment
group as a fixed factor and adjustment for the baseline
number of T2 lesions. The resulting coefficients will be
reported with 95% confidence intervals and their corre-
sponding p-values compared to a two-sided Bonferroni-
adjusted significance level of 0.025 [48].
We do not plan any interim analyses. In the case of
more than 5% missing for the primary endpoint, we plan
to replace missing values in the outcome parameter using
multiple imputation [49] under the missing at random as-
sumption in addition to the complete case analyses.
Table 1 SPIRIT flow diagram of the NAMS study
Visit –1, screening 0, baseline 1, start intervention 2 3 4 5
Month −4 (max) −1 0 3 9 15 18
Informed consent x
Demographics x
Inclusion/exclusion criteria x x x x x x x
Case history x
Medication x x x x x x x
Vital signs x x x x x
Bioelectrical impedance analysis x x x
Anthropometric data x x x x x x
Hand grip strength x x x
Safety laboratory x x x x x
Research laboratory x x x
Urine sample x x x x x
Stool sample x x x
Multiple Sclerosis Quality of Life-54 x x x
Questionnaire on activities x x x
Beck Depression Inventory II x x x
Fatigue Severity Scale x x x
Physical examination x x x
Multiple Sclerosis Functional Composite x x x
Symbol Digit Modalities Test x x x
Six-minute walk test x x x
Expanded Disability Status Scale x x x
Relapse query x x x x x x x
AE/SAE query x x x x x x
MRI x x x
Four-day food record x x x
Nutritional counseling x * * * *
AE adverse event, MRI magnetic resonance imaging, SAE serious adverse event
*There are 10 group sessions for nutritional counseling within 18 months. The fasting diet group has additional meetings during their 7-day-fasts at baseline and
after 6 and 12 months
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As a sensitivity analysis, the primary endpoint will be
analyzed in the per-protocol population. This population
includes all randomized patients who meet the study eli-
gibility criteria and fulfill all compliance criteria through-
out the study.
We intend to perform two subgroup analyses, men vs.
women and MS medication vs. no MS medication, by
adding another main effect for sex or medication,
respectively, as well as an interaction term. These sub-
group analyses will be analyzed in an exploratory man-
ner to generate possible hypotheses for follow-up studies
without adjustment for multiple comparisons. For these,
p-values may not be interpreted as confirmative.
Safety analysis will include calculation of frequencies
and rates of adverse and serious adverse events within
18months of the interventions.
Secondary endpoints will be analyzed in an explorative
manner and descriptives will be given using the mean
and standard deviation for sufficiently normal distrib-
uted metric variables, the median with limits of the
interquartile range (IQR: 25th and 75th percentiles) for
skewed metric or ordinal data, as well as absolute and
relative frequencies for count data.
Discussion
To date, this is the first study that investigates long-term
efficacy of KDs and FDs on T2 hyperintense lesion load
and clinical measures of disease activity and progression
in MS patients. This is also the first study that investi-
gates therapeutic effects of repeated prolonged fasting
combined with daily intermittent fasting. There are sev-
eral reasons for the scarcity of such large-scale, long-
term studies. The most prominent reasons are, of
course, the high demand of financial and human re-
sources. Further, patients often prefer one particular
intervention and are therefore prone to withdraw con-
sent when randomized to an undesired intervention.
Once patients have committed to such a study, it is chal-
lenging to convey dietary interventions in a way that suf-
ficient motivation is aroused. Only this will ensure
dietary adherence for the whole intervention period.
There are some critical aspects of our study design.
First, we include patients with any MS medication or no
medication. From a methodological point of view, in-
cluding only patients on the same treatment or un-
treated patients would have been preferable. However, in
light of the variety of available treatment options, we
would not be able to recruit a sufficient number of pa-
tients with the same medication within an acceptable
time span. Furthermore, by including patients with
different treatments, putative positive results will be
more generalizable. Thus, we decided to include all pa-
tients who have been stable on or off treatment for at
least 6 months. Stratification only differentiates between
treatment and no treatment. Having a stratum for every
treatment would have resulted in a sample size too un-
realistic to recruit and finance. Besides, transferability to
clinical routine is only given if the study population, at
least in principle, reflects the clinical routine with its di-
verse application of different treatment options.
Second, a dietary intervention study cannot be blinded
completely. Thus, expectations and observer bias cannot
be ruled out. However, we try to minimize bias by not
communicating any longitudinal data during the study
to patients and study personnel in contact with them.
Even more important, MRI analysts who evaluate the
primary endpoint are blinded for both clinical data and
interventional allocation.
Third, we undertake MRI scans of both the cranium
and the spinal cord to evaluate disease activity before
study entry in order to prevent selection bias. The study
MRI, however, only analyzes the cranium, thereby
neglecting spinal cord lesions. This entails the risk of
overlooking disease activity. However, newly developing
spinal cord lesions in MS are often associated with clin-
ical symptoms. Thus, they would be recorded as a re-
lapse within regular clinical assessments. Furthermore,
cerebral lesions are more frequent and, therefore, consti-
tute a reliable marker for disease activity.
Fourth, controlling and ensuring adherence to dietary
interventions is rather challenging. This is especially true
in an outpatient setting during such a long study period.
Some patients might be disappointed with their inter-
ventional allocation and surreptitiously include some
features of the desired group into their diet. This can
only be avoided by close and frequent contact between
counselor and patient. Furthermore, changing estab-
lished dietary preferences can be rather challenging and
might lead to compliance issues. Patients with suspected
or known lack of compliance are excluded from the per-
protocol analysis.
One great strength of our study is that patients in the
KD group measure their blood ketones at home. Many
other studies with low-carbohydrate–high-fat diets did
not verify ketosis, which limits the interpretation of re-
sults. Although we do not know the actual concentra-
tions of ketone bodies in the brain, blood ketone
concentrations have been shown to drive the brain’s
overall metabolic rate [50].
Further strengths are the randomized study design,
large sample size, long intervention of 18 months and
blinded outcome assessment. Moreover, we focus on
both MRI-based measures of disease activity and pro-
gression and several patient-related endpoints, such as
fatigue, depression and quality of life.
Considering epidemiological and preclinical data, on the
one hand, and the lack of clinical data, on the other, this
study has the potential to provide essential data on the
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efficacy of KDs and FDs. By analyzing metabolic markers,
oxidative stress and the gut microbiome, we hope to shed
some light on the mechanisms that underlie these dietary
regimens. A better mechanistic understanding might also
be applicable to other neurodegenerative diseases.
In conclusion, KDs and FDs have the potential for a
safe and inexpensive complementary treatment option in
MS and our study might close the gap between promis-
ing preclinical data and the lack of clinical data.
Trial status
This article is based on the study protocol version 1.4 of
23 September 2019. The NAMS started on 24 May
2017. Recruitment will probably continue until March
2020.
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